Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price is charging higher today.

Again.

Shares in the S&P/ASX 300 Index (ASX: XKO) clinical-stage biotechnology company closed yesterday trading for $3.06. In morning trade on Friday, shares are swapping hands for $3.15 apiece, up 2.9%.

This sees the Mesoblast share price up a blistering 1,090% since this time last year.

For some context, the ASX 300 is up 0.8% today and 11.3% over 12 months.

Today's moves come as investors digest Mesoblast's December quarterly report along with a product pipeline update.

Here's what's happening.

Mesoblast share price lifts amid ongoing progress

In the quarter just past, the company – which specialises in allogeneic cellular medicines to treat inflammatory diseases – announced a net operating cash spend of US$10.1 million. While that's still in the red, the net cash spend was down 18% year on year.

Over the three-month period, the Mesoblast share price received a major boost when the company's Ryoncil (remestemcel-L) became the first mesenchymal stromal cell (MSC) therapy approved by the US Food and Drug Administration (FDA) for any indication.

Mesoblast noted that:

FDA approved Ryoncil as the first and only therapy for children aged 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), a life-threatening condition with high mortality rates.

The ASX 300 biotech stock also progressed with its confirmatory Phase 3 trial of rexlemestrocel-L in patients with chronic low back pain, and it reported positive results with its Revascor product for patients with ischemic heart failure and inflammation.

Mesoblast also successfully completed a global private placement, raising US$161 million.

The cash on hand at the end of the quarter was US$38 million, with pro-forma cash after the approximately US$200 million in proceeds raised in January.

What did management say?

Commenting on the results sending the Mesoblast share price higher again today, CEO Silviu Itescu said, "We are committed to making our FDA-approved product Ryoncil available as quickly as possible to the many children with SR-aGVHD in need of life-saving therapy."

Itescu added:

The team has been working relentlessly on finalising product availability, including logistics, regulatory documentation, and contractual arrangements to ensure a successful launch of Ryoncil this quarter.

On the financing front, Itescu said:

The successful financing of US$160 million this month, which provides the company with proforma cash on hand of approximately US$200 million, puts us in a strong position to execute the US commercial launch activities of Ryoncil, to expand the clinical indications of the product, and ensure that commercial manufacturing will meet projected product uptake and demand.

Should you invest $1,000 in Mesoblast Limited right now?

Before you buy Mesoblast Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Healthcare Shares

Up 175% in 12 months: Bell Potter just upgraded this high-flying ASX 200 share

This share has smashed the market in recent times but the gains may not be over.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 25% on big UK news

Investors are sending this ASX healthcare stock rocketing on Friday. But why?

Read more »

two men shake hands on a deal.
Healthcare Shares

Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

This share is rocketing on Friday after accepting a takeover offer.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Earnings Results

Telix share price jumps 13% on FY24 profit surge

This pharma stock has delivered another stunning result. Here's what it reported.

Read more »

Health professional working on his laptop.
Earnings Results

2 ASX 300 healthcare shares making big moves on earnings updates

Let's see what these two shares reported on Thursday.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

2 ASX 200 pharmaceutical shares surging on big US news

Big news is getting investors excited on Wednesday. Let's find out what is happening.

Read more »

Bored man sitting at his desk with his laptop.
Healthcare Shares

The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »